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Abstract Human parechoviruses (HPeV) have been recently
recognized as important viral agents in paediatric infections.
The aims of this study were to investigate the HPeV infection
prevalence in infants <1 month in Spain and, secondly, to
analyse the clinical and epidemiological characteristics of
the infected patients compared with those infected by
enterovirus (EV). Infants <1 month with neurological or sys-
temic symptoms were included in a multicentre prospective
study. EV and HPeV detection by RT-PCR and genotyping
were performed in cerebrospinal fluids (CSF), sera or throat
swabs. Out of the total of 84 infants studied during 2013, 32
were EV positive (38%) and 9 HPeV positive (11%). HPeV-3
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was identified in eight cases and HPeV-5 in one. Mean age of
HPeV-positive patients was 18 days. Diagnoses were fever
without source (FWS) (67 %), clinical sepsis (22 %) and en-
cephalitis (11 %). Leukocytes in blood and CSF were normal.
Pleocytosis (p=0.03) andmeningitis (p=0.001) were significant-
ly more frequent in patients with EV infections than with HPeV.
Conclusions: Although HPeV-3 infections were detected
less frequently than EV, they still account for approximately
10 % of the cases analysed in infants younger than 1 month.
HPeV-3 was mainly associated with FWS and without leukocy-
tosis and pleocytosis in CSF. In these cases, HPeV screening is
desirable to identify the aetiologic agent and prevent unnecessary
treatment and prolonged hospitalization.
What is Known:
• Human parechovirus may be a cause of fever and clinical sepsis in the
neonatal period.
• HPeV-3 might be one of the main agents causing severe neonatal
neurological infections.
What is New:
• This is the first multicenter prospective study focused on newborns and
contributes to a better knowledge of these viral infections. Clinical
characteristics of enterovirus and parechovirus infections are
compared specifically in the neonatal period.
• Knowledge of HPeV infections by paediatricians and neonatologists
can guide the diagnosis of these patients and avoid unnecessary
treatment and prolonged hospitalization.






FWS Fever without source
NICU Neonatal intensive care unit
Introduction
Human parechoviruses (HPeV) are RNAviruses belonging to
the family ofPicornaviridae. Formerly described as echovirus
22 and 23 in the Enterovirus genus, HPeV were reclassified
into their own genus, Parechovirus, in the 1990s based on
genetic differences and biological properties. Then, they were
renamed as HPeV-1 and HPeV-2, respectively [13, 25]. Re-
cently, additional types of HPeV have been reported, and a
total of 16 different types have been recognized to date
(HPeV-1 to 16). The most common genotype detected world-
wide is HPeV-1 followed by HPeV-3. Other types such as
HPeV-2 and HPeV-4 are less common.
Infections with HPeV are prevalent in young children and
have been associated with mild diseases of the respiratory and
gastrointestinal tract but also with serious diseases such as
meningitis, encephalitis and sepsis in young infants [3, 12,
13]. According to recent studies, HPeV-3 might be one of
the main agents causing severe neonatal neurological infec-
tions in Europe [5, 14, 17], although its real incidence is un-
known since HPeV detection is not routinely performed in the
majority of clinical microbiology laboratories. Clinical data
specific for neonates are also scarce.
This study describes the results obtained about the preva-
lence of HPeV infections in children up to 1 month of age in
Spain and the clinical and epidemiological characteristics of
the infected patients over a 1-year period. Furthermore, HPeV
and enterovirus (EV) infections were compared.
Methods
Patients and samples In 2013, a prospective study was con-
ducted in collaboration with 10 Spanish hospitals. The project
was supported with a grant from the Health System (AES;
PI12-00904). The personal data of the patients were protected,
and the study was approved by the Ethics Committee of the
Health Institute Carlos III. Criteria for inclusion were infants
<1 month of age with fever without source (FWS), clinical
sepsis disease or meningitis/encephalitis admitted to the par-
ticipant centres, whose parents agreed to sign the informed
consent. During the hospital stay, a physician filled out a study
questionnaire with the clinical characteristics of the patients.
FWSwas defined as axillary temperature greater than 37.9 °C,
which after an initial examination and laboratory evaluation
has no apparent cause. Aseptic meningitis was defined by a
neonate with fever, irritability, poor feeding, vomiting, or
bulging fontanelle with pleocytosis >30 cells/mm3 in cerebro-
spinal fluid (CSF), with negative CSF culture for bacteria.
Encephalitis was defined as a clinical diagnosis by the attend-
ing neurologist. It may be accompanied or not by CSF
pleocytosis. Electroencephalogram and MRI compatible sup-
port the diagnosis but were not considered essential to it, and a
clinical criterion of the attending neonatologist was consid-
ered enough for inclusion. Meningoencephalitis shares data
from the two latter ones. Clinical sepsis is defined as an infant
with an unwell appearance, with alteration of the paediatric
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assessment triangle (appearance, respiratory and circulatory
items). Exclusion criteria were absence of consent or insuffi-
cient clinical sample.
From January to December 2013, a total of 84 individual
specimens were collected from 84 children up to the age of
1 month, who met the clinical inclusion criteria and were
included in the study. Samples were 71 CSFs (85 %), 12 sera
(14 %) and 1 throat swab (1 %). Mean age of the children was
13+10 days and 46 of them were males (55 %).
Viral detection and typing Enterovirus (EV) and herpes
simplex virus (HSV-1 and 2) and varicella zoster virus
(VZV) screening was performed in the microbiology labora-
tory from the hospital where the patients were admitted or in
the National Centre for Microbiology (CNM), Enterovirus
Laboratory, using commercial molecular methods (Xpert EV,
Cepheid, CA, USA) or Bin-house^ RT-PCRs as previously
described [8, 21].
HPeV was tested at the CNM in those specimens negative
for EV, HSVand VZV, using a real-time RT-PCR designed in
the 5-NCR of the genome [7]. Molecular typing of detected
EVand HPeV was carried out by 3′-VP1 or VP3/VP1 ampli-
fication, respectively, and sequencing [6, 12].
Statistical analysis Clinical and laboratory characteristics of
the HPeV-positive patients were compared with those of the
children infected with EV. A descriptive analysis was per-
formed, expressing qualitative variables as proportions and
quantitative variables as mean and standard deviation or me-
dian and interquartile range when appropriate. The chi-square
test was used to compare groups. A difference with p value
<0.05 was considered to be significant.
Results
Baseline data and frequency of EV and HPeV
infections Out of 84 infants included in the study, 32 were
positive for EV (38 %). No HSV-1 and 2 and VZV were
detected. The 52 negative specimens (47 CSFs, 4 sera and 1
throat swab) were tested for HPeV, with positive detection in 9
(17%) of them. Overall, HPeV detection frequency was 11%.
During the clinical course, other diagnosis were made (urinary
infection, bronchiolitis, gastroenteritis or non-infectious neu-
rologic disease) for 13 of the infants, and those were finally
excluded from the epidemiological and clinical data analysis;
all were EVand HPeV negative (Fig. 1).
Viral detections were not found in any patient with
suspected early-onset sepsis (11 newborns). In addition, four
patients had bacteria positive blood culture, one Staphylococ-
cus epidermidis (contaminated culture), two Streptococcus
agalactiae, and one had a coinfection of Pasteurella
multocida in blood and echovirus 9 in CSF. It was the only
detected virus-bacteria coinfection [1].
Epidemiological and clinical associations of HPeV
infections HPeV-positive samples were from four males
and five females aged between 6 and 31 days (mean
age, 17.6 days). Regarding monthly distribution, most of
the HPeV infections (67 %) were detected between April
and July, with another peak in October (22 %) (Fig. 2).
All viruses were successfully characterized. Eight strains
were HPeV-3 and the other was HPeV-5. All but one
HPeV-positive specimens were found at CSFs. One of
the HPeV-3 was detected in a serum sample. Clinically,
six cases were diagnosed as FWS, two as clinical sepsis
and one as encephalitis (Table 1). Fever was present in all
cases (100 %), 38.6±0.4 °C and lasted a mean of 1.3±
1.1 days. Although all except one of the HPeV were de-
tected in CSF, none of the positive cases had cells in the
range for pleocytosis in children <1 month of age (up to
30 cells/mm3). Protein and glucose were also normal in
CSF. Leucocytes in blood were 8500±5696 cells/mm3. C-
reactive protein and procalcitonine were normal in all pa-
tients. Four of the nine HPeV-infected patients (44 %)
were admitted to the neonatal intensive care unit (NICU).
One of them, diagnosed with encephalitis, had seizures.
None of them needed mechanical ventilation, and all ex-
perienced total recovery except the infant with encephali-
tis who had persistent seizures. All patients received anti-
biotics until the bacterial aetiology could be ruled out.
32 EV + 
84 infants < 1 month 
(FWS, clinical sepsis, neurologic symptoms) 





1 clinical sepsis (S.agalacae) 
5 meningis 
2 encephalis 
52 EV - 
9 HPeV + 43 HPeV - 
30 EV/ HPeV - 
Fig. 1 Flow chart of enrolled and tested patients
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Comparison between EV and HPeV infections Similar to
HPeV infections, 66% of the total of EV-positive samples were
detected between April and July (Fig. 2). Twenty-nine of the 32
EV (91 %) were successfully characterized. All serotypes
found belonged to EV species B. Echovirus (E)-18 was the
most frequently detected type (7/29, 24 %), followed by E-3
and E-5 (4/29, 14 % each) and coxsackievirus (CV)-B3 (3/29,
10 %). Other types also detected in minor proportion were
E-11, E-30, E-6, E-9, E-7, E-17 and CV-B2. The diagnoses
for EV-infected patients were meningitis in 19 cases
(59.4 %), FWS in 12 cases (37.5 %), and clinical sepsis in 1
case (3 %). Clinical data of the infants are shown in Table 1.
When clinical characteristics of EV-infected patients were
compared with those of HPeV-positive children, we observed
significant differences in the pleocytosis in CSF (250±
415 cells/mm3) p=0.015. The odds ratio (OR) for pleocytosis
and EV infection was OR=1.5 (confidence interval CI:1.1–
2.1). CSF protein were also higher in EV group (104±117 vs.
49±17 mg/dL, p=0.03). Furthermore, meningitis diagnosis
was significantly more frequent in EV-positive patients than
in HPeV-infected children (19/32 vs. 0/9, p<0.001). Out of
the 32 EV-positive patients, 23 (72 %) received antibiotic
treatment. Only three EV-positive patients (9 %) needed ad-
mission to the NICU and no sequelae were described in this
group. However, HPeV infection was a risk factor for admis-













Fig. 2 Distribution by month of the enterovirus (EV)- and parechovirus
(HPeV)-positive samples detected in this study
Table 1 Clinical characteristics
of infants with human enterovirus
(EV) and parechovirus (HPeV)
infections
Clinical feature EV HPeV p
(n=32) (n=9)
Male 17 (53 %) 4 (44 %) NS
Age average (days) 17.2+ 7.9 17.6+ 9 NS
Temperature >37.9 °C 31 (97 %) 9 (100 %) NS
Highest temperature 38.5±0.6 38.6±0.4 NS
Fever duration (days) 1.6±1.1 1.3±1.1 NS
Rash 4 (12.5 %) 1 (11 %) NS
Antibiotic treatment 23 (72 %) 9 (100 %) NS
NICU admission 3 (9 %) 4 (44 %) 0.001*
OR=5.2(CI:1.9–14)
Leucocytes (cells/mm3) 10147+4693 8500+5696 NS
Serum CRP (mg/L) 10.8+27 2.6+3.9 NS
Procalcitonine (ng/mL) 0.8+2.7 0.2+0.09 NS
CSF cells/mm3 250+415a 5.7+7 0.015*
OR=1.6(CI:1.1–2.1)
CSF proteins (mg/dL) 104±117a 49±17 0.030*
CSF glucose (mg/dL) 53+10a 50+8 NS
Diagnosis
Fever without source 12 (37.5 %) 6 (67 %) NS
Clinical sepsis 1 (3 %) 2 (22 %) NS
Meningitis 19 (59.4 %) 0 0.001*
Encephalitis 0 1 (11 %) NS
Quantitative variables are expressed as mean and standard deviation
a Excluded a patient coinfected with EVand Pasteurella multocida
NS not significant, NICU neonatal intensive care unit,CSF cerebrospinal fluid,CRP C-reactive protein,OR odds
ratio, CI confidence interval
*p values <0.05
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Discussion
We present a prospective, multicentre study performed during
1 year in Spanish infants up to 1 month of age with suspected
sepsis or meningo-encephalitis or fever without source. EV
was detected in 38 % of the patients and HPeV in 11 %. With
respect to EV infections, other authors found EV incidences in
neonates between 9.5 and 24 % [2, 16, 18, 26]. The high
detection frequency observed in our series might be due to
the study being performed in clinically ill infants with a high
suspicion of viral infection and not as active surveillance.
Besides, not all EV-negative samples collected by the hospi-
tals could be included in the final study, due to absence of
available samples or signed consent forms.
On the other hand, few HPeV epidemiological studies fo-
cused on newborns (infants <30 days) have been published.
Most of them were performed in children (<18 years), and the
presence of the virus in CSF varies from 2.3 to 7 %, whereas
in the general population the percentage decreases to 0.5–
0.8 % [9–11, 23]. As far as we know, there is only one study
from Italy in which 7 (11.6 %) cases of EVand 3 (5 %) cases
of HPeV infections were detected out of 60 neonates with
suspected sepsis or neurological infection [18]. Our higher
HPeV prevalence in the same type of patients (11 %) might
be due to the fact that the Italian study [18] was conducted at
the NICU, reducing the study population and leaving out the
analysis of childrenwho do not require admission to the NICU
(56 % in our series).
In most of the previous studies, HPeV-3 infections have
been described as clearly associated with central nervous sys-
tem infections and sepsis-like illness in neonates and young
infants [4, 15, 22]. Our data supported these findings, as
HPeV-3 was also the predominant genotype identified,
representing 89 % of the total HPeV detected. Only one strain
was identified as HPeV-5, which is an infrequent type reported
in the literature [9–11, 18, 23]. In this study, this type was
detected in a case with FWS, so we cannot conclude that
HPeV type 5 has a proved association with neurological or
systemic diseases in newborns.
Regarding seasonal distribution, in Europe, HPeV infec-
tions are more common in spring and summer, similar to the
EV infections [9–11, 23]. In our series, there is also a predom-
inance of HPeV detection in spring and summer, although we
have only 1 year of enrollment period. Besides, HPeV has
been described to present in biannual cycles in Europe [9,
11, 15]. Previous data in Spain (not published) are consis-
tent with those findings as the detection frequency was
significantly higher in 2011 and 2013 than in 2012, but
further longer surveillance studies are necessary to con-
firm the seasonality and periodicity of the HPeV-3 infec-
tions. This circulation pattern might also explain the high
HPeV incidence found in this study, in comparison with
the previously mentioned Italian one [18].
Recently, Sharp et al [23], in Kansas, found that up to 17%
of the CSF-positive samples of children (<18 years) tested
between June and October 2009 were positive for HPeV, with
HPeV-3 being the predominant type. Clinically, they de-
scribed HPeVinfections with irritability and longer fever, low-
er peripheral leucocytes, absence of pleocytosis, lower CSF
protein and higher CSF glucose compared to EV infections. In
our series, some of these clinical characteristics were also
observed as HPeV-infected patients had lower blood
leucocytes, CSF protein and CSF cells values than those with
EV infection. Furthermore, several studies including the
American one mentioned above reported that admission to
intensive care units were more frequent in HPeV-positive
cases than in those infected by EV, but the prognosis was
generally good [9, 22, 23].We observed the same in our series.
The higher proportion of HPeV-infected children who re-
quired admission to NICU was probably determined by the
low age in an infant with an unwell appearance rather than by
the clinical severity, as there was only one patient with en-
cephalitis who had sequelae. In the literature, however, some
fatal cases were described [19, 20], encephalitis being the
major complication that caused sequelae and deaths.
Another recent study reported that between 50 and 100 %
of HPeV-positive cases had been associated with erythema-
tous rash on the extremities, especially palms and soles, not
always present in the first hours but during evolution [24].
This dermatologic manifestation would be very suspicious
data of HPeV infection in neonates and very young infants
with febrile syndrome. However, these data are not consistent
in the literature; the rash might have gone unnoticed or
showed a different prevalence depending on the area. In the
present study, only 12.5 % of patients showed rash.
In summary, HPeV-3 infections should be suspected in
infants younger than 1 month, with fever but without
leucocytosis and pleocytosis in CSF. In these cases, HPeV
screening in CSF or blood should be incorporated in the rou-
tine viral diagnosis to prevent unnecessary antibiotic treatment
and prolonged hospitalization. The low number of samples
included in this study was a limitation that affects the inci-
dence data of the EVand HPeV infections, but not the results
obtained in relation to the clinical and epidemiological differ-
ences found between both infections. Further studies could
provide more information about the burden of HPeV infec-
tions in newborns.
Acknowledgments This study was partially supported by a grant from
the Spanish National Health Institute PI12-00904.
Conflict of interest The authors declare that they have no conflict of
interest and they do not have a financial relationship with the organization
that sponsored the research.
Author’s contribution María Cabrerizo and Gloria Trallero performed
the detection and genotyping of HPeV. María Cabrerizo and Cristina
Eur J Pediatr (2015) 174:1511–1516 1515
Calvo designed the study, analysed the clinical data and wrote the man-
uscript. María José Pena Gregoria Megías, María Carmen Muñoz
Almagro, María Pilar Romero, Sara Sanbonmatsu-Gámez, Mercedes
Pérez-Ruiz, Manuel Omeñaca, Juan García Costa, Antonio Moreno-
Docón and Nuria Rabella performed the local virological study, drafted
the initial manuscript and approved the final manuscript as submitted.
Amaia Cilla Eva del Amo, Diana Roda, María José Santos-Muñoz, Ana
Isabel Mensalvas and Cristina Calvo recruited the patients and performed
the data collection, contributed to the discussion of the results, and ap-
proved the final manuscript as submitted.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Aguado I, Calvo C, Wilhelmi I, Pablo-Hernando ME, Medina MJ,
Sáez-Nieto JA, Cabrerizo M (2014) Sepsis and meningitis caused
by pasteurella multocida and echovirus 9 in a neonate. Pediatr
Infect Dis J 33:1308–1309
2. Ahmad S, Dalwai A, Al-Nakib W (2013) Frequency of enterovirus
detection in blood samples of neonates admitted to hospital with
sepsis-like illness in Kuwait. J Med Virol 85:1280–1285
3. Baumgarte S, de Souza-Luna LK, Grywna K, Panning M, Drexler
JF, Karsten C, Huppertz HI, Drosten C (2008) Prevalence, types,
and RNA concentrations of human parechoviruses, including a
sixth parechovirus type, in stool samples from patients with acute
enteritis. J Clin Microbiol 46:242–248
4. Benschop KS, Schinkel J, Minnaar RP, Pajkrt D, Spanjerberg L,
Kraakman HC, Berkhout B, Zaaijer HL, Beld MG, Wolthers KC
(2006) Human parechovirus infections in Dutch children and the
association between serotype and disesase severity. Clin Infect Dis
42:204–210
5. Boivin G, Abed Y, Boucher FD (2005) Human parechovirus 3 and
neonatal infections. Emerg Infect Dis 11:103–107
6. Cabrerizo M, Echevarria JE, González I, de Miguel T, Trallero G
(2008) Molecular epidemiological study of HEV-B enteroviruses
involved in the increase in meningitis cases occurred in Spain dur-
ing 2006. J Med Virol 80:1018–1024
7. Cabrerizo M, Calvo C, Rabella N, Muñoz-Almagro C, del Amo E,
Pérez-RuizM, Sanbonmatsu-Gámez S,Moreno-DocónA, OteroA,
Trallero G et study group of Enterovirus and parechovirus infec-
tions in children under 3 years-old, Spain (PI12-00904) (2014)
Design and validation of a real-time RT-PCR for the simultaneous
detection of enteroviruses and parechoviruses in clinical samples. J
Virol Methods 208:125–128
8. Casas I, Tenorio A, Echevarria JM, Klapper PE, Cleator GM (1997)
Detection of enteroviral RNA and specific DNA of herpesviruses
by multiplex genome amplification. J Virol Methods 66:39–50
9. Esposito S, Rahamat-Langendoen J, Ascolese B, Senatore L,
Castellazzi L, Niesters HG (2014) Pediatric parechovirus infec-
tions. J Clin Virol 60:84–89
10. Fischer TK, Midgley S, Dalgaard C, Nielsen AY (2014) Human
parechovirus infection. Denmark Emerg Infect Dis 20:83–87
11. Ghanem-Zoubi N, Shiner M, Shulman LM, Sofer D, Wolf D,
Marva E, Kra-Oz Z, Shachor-Meyouhas Y, Averbuch D, Bechor-
Fellner A, Barkai G, Kinarty A, Gershstein V, Ephros M (2013)
Human parechovirus type 3 central nervous system infections in
Israeli infants. J Clin Virol 58:205–210
12. Harvala H, Robertson I, McWilliam Leitch EC, Benschop K,
Wolthers KC, Templeton K, Simmonds P (2008) Epidemiology
and clinical associations of human parechovirus respiratory infec-
tions. J Clin Microbiol 46:3446–3453
13. Harvala H, Simmonds P (2009) Human parechoviruses: biology,
epidemiology and clinical significance. J Clin Virol 45:1–9
14. Harvala H, McLeish N, Kondracka J, McIntyre CL, McWilliam
Leitch EC, Templeton K, Simmonds P (2011) Comparison of hu-
man parechovirus and enterovirus detection frequencies in cerebro-
spinal fluid samples collected over a 5-year period in Edinburgh:
HPeV Type 3 identified as the most common picornavirus type. J
Med Virol 83:889–896
15. Harvala H, Griffiths M, Solomon T, Simmonds P (2014) Distinct
systemic and central nervous system disease patterns in enterovirus
and parechovirus infected children. J Infect 69:69–74
16. Khetsuriani N, LaMonte A, Oberste MS, Pallansch M (2006)
Neonatal enterovirus infections reported to the national enterovirus
surveillance system in the United States, 1983–2003. Pediatr Infect
Dis J 25:889–893
17. Piñeiro L, Vicente D,Montes M, Hernández-Dorronsoro U, Cilla G
(2010) Human parechoviruses in infants with systemic infection. J
Med Virol 82:1790–1796
18. Piralla A, Mariani B, Stronati M, Maroni P, Baldante F (2014)
Human enterovirus an parechovirus infections in newborns with
sepsis-like illness and neurological disorders. Early Hum Dev
90(Suppl 1):S75–S77
19. Schuffeneckera I, Javouhey E, Gillet Y, Kugener B, Billaud G,
Floret D, Lina B, Morfin F (2012) Human parechovirus infections,
Lyon, France, 2008–10: evidence for severe cases. J Clin Virol 54:
337–341
20. Sedmak G, Nix WA, Jentzen J, Haupt TE, Davis JP, Bhattacharyya
S, Pallansch MA, Oberste MS (2010) Infant deaths associated with
human parechovirus infection in Wisconsin. Clin Infect Dis 50:
357–361
21. Selva L, Martinez-Planas A, García-García JJ, Casadevall R,
Luaces C, Muñoz-Almagro C (2012) Comparison of an in-house
real-time RT-PCR assay with a commercial assay for detection of
enterovirus RNA in clinical samples. Eur J Clin Microbiol Infect
Dis 31:715–719
22. Selvarangan R, Nzabi M, Selvaraju SB, Ketter P, Carpenter C,
Harrison CJ (2011) Human parechovirus 3 causing sepsis-like ill-
ness in children frommidwestern United States. Pediatr Infect Dis J
30:238–242
23. Sharp J, Harrison CJ, Puckett K, Selvaraju SB, Penaranda S, Nix
WA, Oberste MS, Selvarangan R (2013) Characteristicas of young
infants in whom human parechovirus, enterovirus or neither were
detected in cerebrospinal fluid during sepsis evaluations. Pediatr
Infect Dis J 32:213–216
24. Shoji K, Komuro H, Miyata I, Miyairi I, Saitoh A (2013)
Dermatologic manifestations of human parechovirus type 3 infec-
tion in neonates and infants. Pediatr Infect Dis J 32:233–236
25. Stanway G, Joki-Korpela P, Hyypia T (2000) Human
parechoviruses: biology and clinical significance. Rev Med Virol
10:57–69
26. Verboon-Maciolek MA, Krediet TG, van Loon AM, Kaan J,
Galama JM, Gerards LJ, Fleer A (2002) Epidemiological survey
of neonatal non-polio enterovirus infection in the Netherlands. J
Med Virol 66:241–245
1516 Eur J Pediatr (2015) 174:1511–1516
